Cargando…

Kinetic Characterization of Novel HIV-1 Entry Inhibitors: Discovery of a Relationship between Off-Rate and Potency

The entry of HIV-1 into permissible cells remains an extremely attractive and underexploited therapeutic intervention point. We have previously demonstrated the ability to extend the chemotypes available for optimization in the entry inhibitor class using computational means. Here, we continue this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meuser, Megan E., Murphy, Michael B., Rashad, Adel A., Cocklin, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222832/ https://www.ncbi.nlm.nih.gov/pubmed/30081466 http://dx.doi.org/10.3390/molecules23081940

Ejemplares similares

Field-Based Affinity Optimization of a Novel Azabicyclohexane Scaffold HIV-1 Entry Inhibitor
por: Meuser, Megan E., et al.
Publicado: (2019)

Composition and Orientation of the Core Region of Novel HIV-1 Entry Inhibitors Influences Metabolic Stability
por: Karadsheh, Rama, et al.
Publicado: (2020)

Clade-Specific Alterations within the HIV-1 Capsid Protein with Implications for Nuclear Translocation
por: Dick, Alexej, et al.
Publicado: (2022)

Structure, Function, and Interactions of the HIV-1 Capsid Protein
por: Rossi, Eric, et al.
Publicado: (2021)

Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors
por: Jiang, Xiangyi, et al.
Publicado: (2019)

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
por: Eketjäll, Susanna, et al.
Publicado: (2016)

Recent Advances in HIV-1 Gag Inhibitor Design and Development
por: Dick, Alexej, et al.
Publicado: (2020)

Structure–Activity Relationships of a Novel Capsid Targeted Inhibitor of HIV-1 Replication
por: Kortagere, Sandhya, et al.
Publicado: (2014)

The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors
por: Rossi, Fiorella, et al.
Publicado: (2008)

HIV-1 Entry, Inhibitors, and Resistance
por: Lobritz, Michael A., et al.
Publicado: (2010)

Bioisosteric Replacement as a Tool in Anti-HIV Drug Design
por: Dick, Alexej, et al.
Publicado: (2020)

Subtype Differences in the Interaction of HIV-1 Matrix with Calmodulin: Implications for Biological Functions
por: Dick, Alexej, et al.
Publicado: (2021)

HIV-1 Entry and Membrane Fusion Inhibitors
por: Xiao, Tianshu, et al.
Publicado: (2021)

Rapid-kinetics degron benchmarking reveals off-target activities and mixed agonism-antagonism of MYB inhibitors
por: Harada, Taku, et al.
Publicado: (2023)

Discovery of novel Cyclophilin D inhibitors starting from three dimensional fragments with millimolar potencies
por: Grädler, Ulrich, et al.
Publicado: (2019)

Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency
por: Schindler, Christina, et al.
Publicado: (2019)

Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential
por: Rossetti, Thomas, et al.
Publicado: (2022)

Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV
por: Orkin, Chloe, et al.
Publicado: (2022)

Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics
por: De Feo, Christopher J, et al.
Publicado: (2014)

HIV envelope: challenges and opportunities for development of entry inhibitors
por: Caffrey, Michael
Publicado: (2011)

Perspective on the Relationship between GABA(A) Receptor Activity and the Apparent Potency of an Inhibitor
por: Germann, Allison L., et al.
Publicado: (2022)

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor
por: Miller, Duncan C., et al.
Publicado: (2022)

P04-37. Kinetic and thermodynamic factors determine HIV-1 neutralizing potency of MPER-specific antibodies
por: Ruprecht, C, et al.
Publicado: (2009)

Erratum: Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential
por: Frontiers Production Office,
Publicado: (2022)

Corrigendum: Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential
por: Rossetti, Thomas, et al.
Publicado: (2023)

Analysis of “On/Off” Kinetics of a CETP Inhibitor Using a Mechanistic Model of Lipoprotein Metabolism and Kinetics
por: Lu, J, et al.
Publicado: (2015)

The Effect of N-Terminal Cyclization on the Function of the HIV Entry Inhibitor 5P12-RANTES
por: F. Nguyen, Anna, et al.
Publicado: (2017)

Assessment of HIV-1 entry inhibitors by MLV/HIV-1 pseudotyped vectors
por: Siegert, Sandra, et al.
Publicado: (2005)

Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants
por: Acharya, Arpan, et al.
Publicado: (2021)

Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry
por: Wang, Haofeng, et al.
Publicado: (2023)

A novel small-molecule inhibitor of HIV-1 entry
por: Heredia, Alonso, et al.
Publicado: (2015)

Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry
por: Preobrazhenskaya, Maria N., et al.
Publicado: (2006)

Monomerization of Viral Entry Inhibitor Griffithsin Elucidates the Relationship between Multivalent Binding to Carbohydrates and anti-HIV Activity
por: Moulaei, Tinoush, et al.
Publicado: (2010)

Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore‐based virtual screening approach
por: Mirza, Muhammad Usman, et al.
Publicado: (2020)

Alprazolam Prompts HIV-1 Transcriptional Reactivation and Enhances CTL Response Through RUNX1 Inhibition and STAT5 Activation
por: Lin, Angel, et al.
Publicado: (2021)

Peptide Triazole Thiol Irreversibly Inactivates Metastable HIV-1 Env by Accessing Conformational Triggers Intrinsic to Virus–Cell Entry
por: Ang, Charles Gotuaco, et al.
Publicado: (2021)

Elite Suppressor–Derived HIV-1 Envelope Glycoproteins Exhibit Reduced Entry Efficiency and Kinetics
por: Lassen, Kara G., et al.
Publicado: (2009)

The orally bioavailable allosteric CXCR4 HIV-1 entry inhibitor AMD11070
por: Fricker, Simon, et al.
Publicado: (2012)

Discovery of Desmuramylpeptide NOD2 Agonists with Single-Digit Nanomolar Potency
por: Guzelj, Samo, et al.
Publicado: (2022)

HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants
por: Smith, Steven J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_edilupbedhnkcnffsfgl24p7k7